Novartis Ag (NVSEF) Non-Current Debt (2009 - 2025)

Novartis Ag has disclosed Non-Current Debt across 12 years of filings, most recently posting $27.9 billion for Q4 2025.

• Non-Current Debt for Q4 2025 came in at $27.9 billion, up 30.75% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.9 billion (up 30.75% YoY), and the FY2025 annual result was $27.9 billion, up 30.75% from the prior year.
• Non-Current Debt came in at $27.9 billion for Q4 2025 at Novartis Ag, up from $22.5 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $27.9 billion in Q4 2025 to a low of $18.3 billion in Q2 2023.
• The 5-year median for Non-Current Debt is $21.8 billion (2022), against an average of $21.8 billion.
• Across the five-year window, Non-Current Debt declined 17.87% in 2023 and soared 30.75% in 2025, its largest moves.
• Novartis Ag's Non-Current Debt stood at $22.9 billion in 2021, then fell by 11.61% to $20.2 billion in 2022, then retreated by 8.93% to $18.4 billion in 2023, then grew by 15.89% to $21.4 billion in 2024, then jumped by 30.75% to $27.9 billion in 2025.
• The last three Non-Current Debt figures came in at $27.9 billion (Q4 2025), $22.5 billion (Q2 2025), and $21.4 billion (Q4 2024), per Business Quant data.